Versus Systems Inc (VS) Stock News

The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.

Rosen Law Firm is encouraging investors who purchased securities of Microvast Holdings (MVST) between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion. The lead plaintiff deadline is September 21, 2026. Similar class action notices are being issued for PROCEPT BioRobotics and TransMedics Group.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Microvast Holdings, with allegations that the company made false statements about margin targets and the Huzhou Phase 3.2 expansion completion timeline. The lead plaintiff deadline is September 21, 2026. Similar notices are being issued for Hub Group and Peabody Energy.

A class action lawsuit has been filed against Microvast Holdings, Inc. (NASDAQ: MVST) for alleged securities fraud. The complaint alleges that company executives made materially false and misleading statements regarding business operations, margin targets, and the Huzhou Phase 3.2 expansion timeline. The lawsuit covers investors who purchased Microvast securities between April 1, 2025 and March 16, 2026. The stock experienced significant declines following revelations of inventory issues, delayed production capacity expansion, and a sharp drop in gross margins from 36% to 1%.

Law Offices of Howard G. Smith announced class action lawsuits against three publicly-traded companies for securities fraud. Insulet Corporation faces allegations of defective manufacturing controls, Microvast Holdings is accused of overstating margin targets and expansion timelines, and Hub Group is charged with material misstatements in financial reporting. Investors have until late August and September 2026 to file lead plaintiff motions.

Rosen Law Firm is urging investors who purchased Microvast Holdings securities between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management issues, and delays in the Huzhou Phase 3.2 expansion completion. The lead plaintiff deadline is September 21, 2026.

Rosen Law Firm is reminding investors who purchased Microvast Holdings securities between April 1, 2025 and March 16, 2026 of an important September 21, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management issues, and delays in the Huzhou Phase 3.2 expansion completion.

Rosen Law Firm has filed class action lawsuits against Microvast Holdings, Inc. and other companies on behalf of investors who purchased securities during specified periods. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and the completion of facility expansions. Investors who purchased securities during the class period may be eligible for compensation.

Rosen Law Firm has filed a class action lawsuit on behalf of Microvast Holdings investors who purchased securities between April 1, 2025 and March 16, 2026. The lawsuit alleges that defendants made materially false and misleading statements regarding margin targets, inventory management issues, delays in commercial vehicle rollouts, and the completion timeline of the Huzhou Phase 3.2 expansion. Investors must move the court by September 21, 2026 to serve as lead plaintiff.

Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.

Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.

VSORA, a French semiconductor company, announced a strengthened funding round led by Ardian to accelerate commercialization of its Jotunn8 AI inference processor. The round includes investments from Otium, XAnge, NJJ Capital, Capgemini, CloudHQ, SPRIND, EIC Fund, Omnes Capital, and Critical Path Ventures. The funding will support large-scale deployments and a larger financing round planned for 2027 to fuel international expansion.

Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.

The article compares two Vanguard international ETFs: VXUS (Total International Stock ETF) and VSS (FTSE All-World ex-US Small-Cap ETF). Both offer low fees and broad international exposure, but VSS focuses on small-cap stocks and has delivered higher annualized returns (9.79% since 2009) compared to VXUS (6.73% since 2011), though with greater volatility. The choice between them depends on individual risk tolerance.

Four European entities have formed a strategic partnership to develop and deploy sovereign AI inference chips in Europe. VSORA's Jotunn8 processor will be integrated into Scaleway's cloud infrastructure with ZML's software layer, supported by the Île-de-France Region, aiming to reduce Europe's dependence on imported advanced AI chips and establish a competitive European AI semiconductor ecosystem.

Mizuho analyst Ann Hynes raised her CVS Health price target to $115 per share, implying 13% upside from current levels. The article suggests CVS could see even greater upside potential, potentially reaching $150 per share if it achieves a valuation multiple similar to UnitedHealth Group, given its transformation into a diversified healthcare services company and expected double-digit earnings growth.

PAVS announced a $10 million registered direct offering of 50 million Class A ordinary shares at $0.20 per share. The offering is expected to close on June 16, 2026. Proceeds will be used for evaluating strategic acquisition opportunities in consumer products, wellness, fitness, lifestyle, and digital commerce sectors, as well as working capital and general corporate purposes.

DevvStream Corp. (NASDAQ:DEVS) surged 19.37% in pre-market trading to $0.55 after announcing a $6 million Series A Convertible Preferred Stock placement with EEME Energy SPV I, LLC. The company will invest $5 million in Southern Energy Renewables Inc. and use $1 million for working capital. Additionally, DevvStream terminated its equity line agreement with Helena Global Investment Opportunities I Ltd. to simplify its capital structure ahead of a planned business combination with XCF Global Inc., a sustainable aviation fuel producer.

CVS Health's dividend is sustainable despite the company pausing annual increases. With Q1 2026 operating cash flow of $4.2 billion and expected annual cash flow of at least $9.5 billion, CVS comfortably covers its $3.39 billion projected dividend payout (representing just over 20% of cash flow). The company's 2.89% dividend yield significantly exceeds the S&P 500 average, making it an attractive income investment with minimal risk of elimination.

H1, an AI-powered healthcare platform for identifying and engaging physicians, secured a $40M investment led by CVS Health Ventures. The funding follows successful collaborations between the companies, including an AI model that improved healthcare provider directory accuracy. H1 serves 85% of top 20 pharma companies and 9 out of 10 top health plans, and is on track to achieve above Rule of 40 profitability metrics in 2026.

VS Media Holdings Limited (NASDAQ: VSME), a digital creator network company, announced plans to enter the AI Smart Living sector to explore new growth opportunities. The company intends to leverage its existing media resources, creator networks, and brand communications capabilities to develop smart home products, AI-enabled lifestyle services, and intelligent community solutions. VS Media plans to establish international business platforms and pursue strategic partnerships, though the company cautions that the business remains in early planning stages with no guaranteed outcomes.

CVS Health stock has surged 24% over the past month following strong Q1 earnings that beat analyst expectations, with revenue up 6.2% to $100.4B and EPS up 62% to $2.30. The company raised full-year guidance and is benefiting from improved margins in its Aetna insurance segment and growth from Rite Aid store acquisitions. However, the company carries significant debt of $86.4B in long-term obligations, though it is gradually reducing overall leverage.

International small-cap stocks were hit hard during the Iran-U.S. war, dropping nearly 12% from late February through March due to energy shocks and geopolitical concerns. However, they have since rebounded strongly, recovering most losses. The Vanguard FTSE All-World Ex-US Small-Cap ETF (VSS) is highlighted as an attractive long-term buy opportunity, having gained 10% since March 30 and 12% year-to-date, as valuations remain depressed and fundamental growth drivers remain intact.

Vishay Intertechnology introduced four series of 3000 W transient voltage suppressors (TVS) in the new DFN6546A package with wettable flanks. The automotive-grade and industrial-qualified devices feature a compact 6.5 mm x 4.6 mm footprint with 0.88 mm profile, offering twice the power dissipation of comparable packages while reducing volume by up to 76%. Samples and production quantities are available now with 12-week lead times.